Creo Medical Group
plc
("Creo"
the "Company" or the "Group")
Notice of Results
Creo
Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for
pre-cancer and cancer patients, will announce its audited full year results
for the year ended 31 December 2023 on Wednesday 15 May
2024.
Investor
Presentation
Craig
Gulliford, Chief Executive Officer, and Richard Rees, Chief
Financial Officer, will provide a live presentation covering the
full year results via the Investor Meet Company platform on
Wednesday 15 May at 15:00 BST.
The
presentation is open to all existing/potential shareholders and
analysts. Questions can be submitted at any time during the live
presentation.
Investors can sign up to Investor
Meet Company at no additional cost and register in advance to meet
Creo Medical Group plc via: https://www.investormeetcompany.com/creo-medical-group-plc/register-investor
Investors who already follow Creo
Medical Group plc on the Investor Meet Company platform will
automatically be invited.
-Ends-
Enquiries:
|
Creo Medical Group
plc
|
www.creomedical.com
|
|
Richard Rees (CFO)
|
+44 (0)1291 606 005
|
|
|
|
|
Cavendish Capital
Markets Limited
|
+44 (0)20 7397 8900
|
|
Stephen Keys / Camilla Hume (NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan Brown
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780 or
creo@walbrookpr.com
|
|
Paul McManus / Sam Allen
Phillip Marriage
|
Mob: +44 (0)7980 541 893 /
+44 (0)7502 558 258
+44
(0)7867 984 082
|
About Creo
Medical
Creo Medical is a medical device company focused on
the development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes
through the development and commercialisation of a suite of
electrosurgical medical devices, each enabled by CROMA, powered by
Kamaptive. The Group has developed the CROMA powered by Kamaptive
full-spectrum adaptive technology to optimise surgical capability
and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less-invasive and more
cost-efficient option for procedures.
For more information, please refer to the website
www.creomedical.com